AKBLF — Stock activity · TradeandTell
AKBL AKBLF $37.92 -$2.73 (-6.73%) prev close
Held by
0
portfolios on TandT
Avg position size
—
of holders' portfolios
52-week range
$31.35 – $40.65
71% from low
Price Valuation Financials Segments
Held by traders on TradeandTell No one on the platform currently holds AKBLF.
Super investors & insiders Institutions holding (13F)
No tracked institution reports a position in AKBLF as of their last filing.
Insider activity (SEC Form 4)
Dividend history TTM yield · 4.22% ($1.60/share)
Ex-date Per share Pay date 2026-03-18 $1.6000 2026-03-19
Stock splits Execution date Ratio 2022-03-29 20-for-1
Recent trades on TradeandTell No one on the platform has traded AKBLF yet.
Report a bug Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Analyst estimates (consensus) Year Est. revenue Growth Est. EPS EPS range Fwd P/E # Analysts 2026 $7.3B +16.4% $6.55 $6.47–$6.62 5.8× 1 2027 $8.2B +13.1% $7.38 $7.29–$7.46 5.1× 1 2028 $9.3B +13.0% $8.35 $8.25–$8.44 4.5× 1 2029 $10.4B +11.4% $10.20 $10.07–$10.31 3.7× 1
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Earnings surprises Beat consensus in 5 of the last 8 reported quarters
Reported Est. EPS Actual Surprise 2026-05-04 $0.26 $0.31 +17.7% 2026-02-20 $0.20 $0.19 -7.7% 2025-11-12 $0.16 $0.22 +40.2% 2025-08-21 $0.20 $0.19 -7.6% 2025-05-06 $0.20 $0.24 +20.4% 2025-02-19 $0.14 $0.11 -22.0% 2024-11-14 $0.12 $1.00 +744.6% 2024-08-23 $0.09
DCF fair valuemodel estimate Peer comparison Symbol Price Today Mkt cap P/E AKBLF ALK-Abelló A/S $37.91 +0.00% $7.6B — CAMRF Camurus AB $64.00 +9.38% $3.8B — CLCGY Clicks Group Limited $26.15 -1.54% $3.1B — CSMYF COSMOS Pharmaceutical Corporation $37.06 +0.00% $2.9B — FLMNY Fielmann Group AG $9.10 +0.00%
GNGBF Getinge AB (publ) $22.49 +0.00% $5.7B —
GNNSF Genscript Biotech Corporation $3.21 -0.93% $7.0B —
Source: Financial Modeling Prep · peers by sector/industry
$AKBLF chatter on StockTwits @Stocktwits
$SPRY $NDAQ $AKBLF
ALK expects 425mm USD peak revenue from Neffy not including urticaria.
View on StockTwits ↗ $AKBLF ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy
View on StockTwits ↗ $AKBLF ALK-ABELLÓ – DENMARK’S NEXT PHARMA HIGHFLYER?
https://www.undervalued-shares.com/weekly-dispatches/alk-abello-denmarks-next-pharma-highflyer/aff/9/
View on StockTwits ↗ ALK-Abelló – Denmark's next pharma highflyer?
You are unlikely to have heard of $AKBLF, but it's a hidden champion that could yet get a lot more attention over the years to come.
The company commands a 35% global market share in immunotherapies for allergies. Just 1% of its 500m strong target market is using these therapies yet, which leaves massive potential for growth.
ALK-Abelló's share price is down 40% over the past two years. Is now the right time to add this company to your watchlist?
https://www.undervalued-shares.com/weekly-dispatches/alk-abello-denmarks-next-pharma-highflyer
View on StockTwits ↗ $AKBLF - Will trending continue? https://www.macroaxis.com/valuation/AKBLF/ALK-Abell-AS #stocks #earnings
View on StockTwits ↗ ALK-Abelló A/S upgraded by Danske to buy. www.marketbeat.com/stocks/OTC/AKBLF/price-target/ $AKBLF
View on StockTwits ↗ ALK-Abelló A/S upgraded by Danske to hold. www.marketbeat.com/stocks/OTC/AKBLF/price-target/ $AKBLF
View on StockTwits ↗ ALK-Abelló A/S downgraded by Danske to sell. www.marketbeat.com/stocks/OTC/AKBLF/price-target/ $AKBLF
View on StockTwits ↗ ALK-Abelló A/S downgraded by DNB Markets to hold. www.marketbeat.com/stocks/OTC/AKBLF/price-target/ $AKBLF
View on StockTwits ↗ $AKBLF U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
https://www.stocktitan.net/news/AKBLF/u-s-fda-approves-alk-s-odactra-r-house-dust-mite-allergen-extract-crtk6a670g6b.html
View on StockTwits ↗ ALK-Abelló A/S upgraded by SEB Equities to buy. 140.00 PT. https://www.marketbeat.com/r/1846672 $AKBLF
View on StockTwits ↗ ALK-Abelló A/S downgraded by Danske to hold. https://www.marketbeat.com/r/1841823 $AKBLF
View on StockTwits ↗ ALK-Abelló A/S initiated by Bryan, Garnier & Co at buy. 160.00 PT. https://www.marketbeat.com/r/1818240 $AKBLF
View on StockTwits ↗ ALK-Abello A/S upgraded by Danske to buy. https://www.marketbeat.com/r/1701034 $AKBLF
View on StockTwits ↗ Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
